Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Nasdaq 100 Movers: CELG, PYPL

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/20/2017 | 04:26pm CEST

In early trading on Friday, shares of PayPal Holdings (PYPL) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.4%. Year to date, PayPal Holdings registers a 81.3% gain.

And the worst performing Nasdaq 100 component thus far on the day is Celgene Corp. (CELG), trading down 9.9%. Celgene Corp. is showing a gain of 5.8% looking at the year to date performance.

Two other components making moves today are Regeneron Pharmaceuticals (REGN), trading down 2.1%, and Maxim Integrated Products (MXIM), trading up 4.6% on the day.

© BNK Invest, source Videos

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
10/20 NASDAQ 100 MOVERS : Celg, pypl
10/19 REGENERON PHARMACEUTICALS : Patent Application Titled "Predictive and Prognostic..
10/19 REGENERON PHARMACEUTICALS : Science Magazine Ranks Regeneron #1 Biopharma Employ..
10/18 SANOFI SA (ADR)(NYSE : SNY), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Dupixen..
10/18 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Phase 2 Study Results f..
10/18 SANOFI : and Regeneron Announce Positive Phase 2 Study Results for Dupilumab
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17 IBD Announces First Annual Biotech Innovator Awards
10/17 REGENERON PHARMACEUTICALS : to Report Third Quarter 2017 Financial and Operating..
10/16 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Phase 2 Study Results f..
More news
News from SeekingAlpha
10/20 Too-high expectations for Dupixent in asthma reason for Regeneron downgrade -..
10/20 Premarket analyst action - healthcare
10/17 VALUE SYSTEM : Amgen Looks Undervalued
10/17 The Medicines Company May Not Be The Best Investment In 2017
10/16 Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients ..
Financials ($)
Sales 2017 5 746 M
EBIT 2017 2 409 M
Net income 2017 1 338 M
Finance 2017 2 180 M
Yield 2017 -
P/E ratio 2017 37,62
P/E ratio 2018 34,16
EV / Sales 2017 7,69x
EV / Sales 2018 6,82x
Capitalization 46 395 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 496 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS19.69%46 395
GILEAD SCIENCES11.73%106 054
VERTEX PHARMACEUTICALS110.07%38 985
ACTELION23.81%29 840
GENMAB14.75%12 865
EXELIXIS, INC.84.17%7 985